






Bonded-Phase Selectivity Separation of Local Anesthetics

Application
Pharmaceutical
Robert Ricker


SB C18
(Agilent P/N: 883975-902)




SB C8
(Agilent P/N: 883975-906)




SB C3
(Agilent P/N: 883975-909)



SB Phenyl
(Agilent P/N: 883975-912)



SB CN
(Agilent P/N: 883975-905)



- | |
|-----------------|
| 1. Procaine |
| 2. Lidocaine |
| 3. d-Cinchonine |
| 4. Butacaine |
| 5. Tetracaine |

Highlights

- *Change of bonded-phase type is useful as a tool to change selectivity of a separation.*
- *Note reversal of order for peaks 4 and 5 on SB-C18, and peaks 2 and 3 on SB-C8 and SB-C18. Also, note lack of resolution between peaks 1-3 for SB-CN.*
- *Improved peak shape on ZORBAX results from more desirable silanol interactions.*

Conditions:
ZORBAX SB (4.6 x 150 mm) 1.5 mL/min, 10 μ L, 26°C, Detect. UV (254 nm)
Mobile Phase: (0-100%B in 18.8 min.)
A: 50 mM NaH_2PO_4 pH 2.5 in 95% H_2O / 5% ACN
B: 50 mM NaH_2PO_4 pH 2.5 in 47% H_2O /53% ACN



Agilent Technologies

*Robert Ricker is an application chemist
based at Agilent Technologies, Wilmington,
Delaware.*

For more information on our products and
services, visit our website at:
www.agilent.com/chem

Copyright© 2002 Agilent Technologies, Inc.
All Rights Reserved. Reproduction,
adaptation or translation without prior
written permission is prohibited, except as
allowed under the copyright laws.

Agilent shall not be liable for errors
contained herein or for incidental or
consequential damages in connection with
the furnishing, performance, or use of this
material.

Information, descriptions, and specifications
in this publication are subject to change
without notice.

Printed in the USA
April 25, 2002
5988-6424EN



Agilent Technologies